Abstract Number: 1632 • 2013 ACR/ARHP Annual Meeting
Identification Of a Novel Systemic Lupus Erythematosus Risk Locus Between FCHSD2 and P2RY2 In Koreans
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, heterogeneous autoimmune disorder characterized by inflammation, loss of tolerance to self-antigens, and dysregulated interferon responses. Although >40…Abstract Number: 1633 • 2013 ACR/ARHP Annual Meeting
Sub-Phenotype Mapping In Systemic Lupus Erythematosus Identifies Multiple Novel Loci Associated With Circulating Interferon Alpha
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a phenotypically heterogeneous complex disease. Our previous work has documented significant genetic heterogeneity, with some well-validated risk factors demonstrating…Abstract Number: 1634 • 2013 ACR/ARHP Annual Meeting
Genome-Wide Transcriptional Profiling Of Isolated Immune Cell Populations From SLE Patients With Different Ancestral Backgrounds
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex multi-system autoimmune disease of uncertain etiology. Different ancestral backgrounds demonstrate different clinical manifestations and autoantibody profiles. Whole…Abstract Number: 1635 • 2013 ACR/ARHP Annual Meeting
Identification Of Novel Genetic Associations Within Major Histocompatibility Complex (MHC) Class I and Class II In Systemic Lupus Erythematosus (SLE) Patients: An Examination Of Epitopes Of Early Autoimmunity
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production, multiple organ involvement, strong genetic predisposition and specifically, to be associated with…Abstract Number: 1636 • 2013 ACR/ARHP Annual Meeting
Pro-Inflammatory HDL and Subclinical Atherosclerosis Are Associated With Altered Expression Of Epigenetic and Oxidative Stress-Related Gene Transcripts In SLE
Background/Purpose: Premature atherosclerosis is widely recognized as a significant co-morbid condition of systemic lupus erythematosus (SLE), but exact mechanisms are unknown. Although traditional cardiovascular risk…Abstract Number: 1637 • 2013 ACR/ARHP Annual Meeting
IKZF1 Modulates PP2Ac Expression Through An Intronic Binding Site
IKZF1 modulates PP2Ac expression through an intronic binding siteKamalpreet Nagpal1, Katsue Sunahori2, George C. Tsokos11Department of Medicine, Division of Rheumatology, Beth Israel Deaconess Medical Center,…Abstract Number: 1638 • 2013 ACR/ARHP Annual Meeting
Concurrent Autoimmune Disease and Autoantibodies In a Large, Multi-Racial Cohort Of First Degree Blood Relatives Of SLE Patients
Background/Purpose: First degree relatives (FDRs) of SLE patients have an increased risk of developing autoantibodies and/or autoimmune disorders. Between 20% and 40% of FDRs develop…Abstract Number: 1639 • 2013 ACR/ARHP Annual Meeting
GWAS In Hispanic and Latin American Individuals Enriched For Amerindian Ancestry Identifies a New Locus Associated With Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE), a chronic autoimmune disease with a strong genetic component, exhibits a 9:1 female to male ratio and disproportionate impact on…Abstract Number: 1640 • 2013 ACR/ARHP Annual Meeting
Methotrexate Treatment Affects Effector, But Not Regulatory T Cells in Juvenile Idiopathic Arthritis
Background/Purpose: The balance between regulatory (Treg) and effector T cells (Teff) is crucial for immune regulation in juvenile idiopathic arthritis (JIA). How methotrexate (MTX), the…Abstract Number: 1641 • 2013 ACR/ARHP Annual Meeting
Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B
Background/Purpose: Adoptive transfer of regulatory T cells (Tregs) represents a promising strategy for treatment of auto- and alloimmunity. However, it is difficult to obtain therapeutically…Abstract Number: 1642 • 2013 ACR/ARHP Annual Meeting
CD25+CD39+ Regulatory T Cells Are Enriched At The Site Of Inflammation Of Patients With Rheumatoid Arthritis and Impaired In Suppressing IL-17A Secretion
Background/Purpose: Regulatory T cells (Tregs) are important for the maintenance of self-tolerance and are implicated in the origin of autoimmunity. Despite enrichment of Tregs in…Abstract Number: 1603 • 2013 ACR/ARHP Annual Meeting
Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus
Background/Purpose: Belimumab treatment in autoantibody-positive systemic lupus erythematosus (SLE) patients for up to 76 weeks results in sustained reduction in several circulating B cell subsets,…Abstract Number: 1604 • 2013 ACR/ARHP Annual Meeting
Effects Of Chronic Treatment With Blisibimod, An Inhibitor Of B Cell Activating Factor, On Renal and Inflammation Biomarkers In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod on renal and inflammation biomarkers in patients with SLE during the phase 2b clinical trial PEARL-SC (NCT01162681)…Abstract Number: 1605 • 2013 ACR/ARHP Annual Meeting
Post-Marketing Experience With Belimumab In U.S. Lupus Centers: Data From The Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry
Background/Purpose: Much of the published experience with belimumab in lupus patients has derived from clinical trials. We examined the non-sponsored experience with belimumab in routine…Abstract Number: 1606 • 2013 ACR/ARHP Annual Meeting
Overview Of The Safety Of Epratuzumab In Systemic Lupus Erythematosus
Background/Purpose: The efficacy and safety of epratuzumab, a monoclonal antibody targeting CD22, has been evaluated in patients with moderate-to-severe systemic lupus erythematosus (SLE). A pooled…